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Objective: To determine [1] expression levels of both DNAmethyltransferases (DNMTs) andmethyl-CpG-binding
domain proteins (MBDs) in human endometrium throughout the menstrual cycle and in eutopic and ectopic
endometrium of patients with endometriosis and [2] hormone responsiveness of DNMT and MBD expression in
explant cultures of proliferative phase endometrium.
Design: In vitro study.
Setting: Academic medical center.
Patient(s): Premenopausal women with and without endometriosis.
Intervention(s): Explant cultures of proliferative phase endometrium were treated with vehicle, 17b-E2, or
a combination of E2 and P (E2 þ P) for 24 hours.
Main Outcome Measure(s): Expression levels of DNMT1, DNMT2, and DNMT3B and MBD1, MBD2, and
MeCP2 with use of real-time quantitative polymerase chain reaction.
Result(s): Expression levels of DNMT1 and MBD2 were significantly higher in secretory-phase endometrium
compared with proliferative endometrium and menstrual endometrium. In explant cultures, treatment with E2 þ
P resulted in significant up-regulation of DNMT1 and MBD2. Expression levels of several DNMTs and MBDs
were significantly lower in endometriotic lesions compared with eutopic endometrium of women with
endometriosis and disease-free controls.
Conclusion(s): These findings suggest a role for DNMTs andMBDs in the growth and differentiation of the human
endometrium and support the notion that endometriosis may be an epigenetic disease. (Fertil Steril 2011;95:
1421–7.
2011 by American Society for Reproductive Medicine.
)
Open access under the Elsevier OA license.Key Words: Endometriosis, endometrium, DNA methylation, epigenetics, DNMT, MBDEndometriosis is a benign gynecologic disorder that is characterized
by the presence of endometrial glands and stroma at ectopic sites
outside the uterine cavity. Its exact pathogenesis remains enigmatic.
Recent reports support a role for epigenetic processes in the patho-
genesis of endometriosis (1–4). Epigenetics refers to the study of
heritable changes in gene expression that occur without changes in
the underlying DNA sequence (5).
The most studied epigenetic alteration is DNA methylation,
which refers to the addition of a methyl group to the 50 position of
cytosines that precede a guanine in the DNA sequence, the CpG
dinucleotide. Unmethylated CpGs are clustered in CpG islands
and often are associated with transcriptional start sites in promoter
regions. Nowadays it is widely recognized that promoter hyperme-
thylation is associated with condensed chromatin and silencing of
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two components, DNA methyltransferases (DNMTs) and methyl-
CpG-binding domain proteins (MBDs). Deoxyribonucleic acid
methyltransferases are enzymes that catalyze the addition of methyl
groups to CpG dinucleotides. DNMT1 is regarded as the major
enzyme responsible for maintaining existing DNA methylation
patterns during replication. DNMT3A and DNMT3B are thought
of as de novo methyltransferases that are involved in the
postreplicative methylation of previously unmethylated DNA.
Finally, DNMT2 is an enzyme with strong sequence similarities
with 5-methylcytosine methyltransferases of both prokaryotes and
eukaryotes but was shown not to methylate DNA (6).
The crosstalk betweenDNAmethylation and histonemodifications
is established by a family of proteins that contain a methyl-CpG bind-
ing domain, commonly known as MBD proteins. On the basis of
several studies (7, 8), a model has been proposed for DNA
methylation–mediated transcriptional silencing. According to this
model, MBDs specifically recognize and subsequently bind to
methylated CpGs and recruit histone deacetylases (HDACs). The
HDAC removes acetyl groups from the lysines on histone tails,
resulting in chromatin condensation and transcriptional inactivation.
The process of gene silencing therefore requires the combined
action of both DNMTs and MBDs. To date, five MBDs have been
cloned: MeCP2, MBD1, MBD2, MBD3, and MBD4. Of these,Fertility and Sterility Vol. 95, No. 4, March 15, 2011
1421ociety for Reproductive Medicine, Published by Elsevier Inc.
Open access under the Elsevier OA license.
MeCP2, MBD1, and MBD2 have been shown to function as
transcriptional repressors (9).
A significant correlation was demonstrated between DNA meth-
ylation and the expression of progesterone receptor in normal endo-
metrium (10), suggesting that DNA methylation may be involved in
steroid-hormone–dependent endometrial growth and differentia-
tion. In addition, overexpression of steroidogenic factor 1 and estro-
gen receptor b in endometriotic tissue was shown to be the result of
demethylation of the gene promoters (1, 2).
To date, two studies addressing DNMT expression in endome-
trium (11) and endometriosis (12) have been performed. However,
these studies have focused on DNMT expression solely, and, so
far, no studies reporting MBD expression in these tissues are known.
Therefore, the aim of this study was to investigate the expression
levels of both DNMTs and MBDs in [1] normal endometrium
throughout the menstrual cycle and [2] eutopic and ectopic endome-
trium of women with endometriosis. A second aim was to investi-
gate hormone responsiveness of DNMT and MBD expression. The
presence of DNMTand MBD proteins in these tissues was assessed
by immunohistochemistry.MATERIALS AND METHODS
Tissues
As described in more detail later, tissues were collected in two different
clinics, the Maastricht University Medical Center, in Maastricht, the Nether-
lands, and the Leuven Fertility Clinic in Leuven, Belgium.
Tissues collected in the Maastricht University Medical
Center Endometrial tissue was collected from 23 women with regular
menstrual cycles who underwent surgery for benign indications other than
endometriosis in the Maastricht University Medical Center. The tissue was
collected from hysterectomy specimens or by Pipelle biopsies during laparos-
copy (Pipelle catheter;Unimar Inc., Prodimed,Neuilly-en-Thelle, France).The
women were documented not to be taking any kind of steroid medication. All
women signed an informed consent, as required by the protocol approved by
the Medical Ethical Committee of the Maastricht University Medical Center.
Of the 23 biopsy specimens, 3 were collected in the menstrual phase, 8 in
the proliferative phase, and another 12 in the secretory phase of the menstrual
cycle. Each biopsy sample was divided in three parts: the first part was imme-
diately frozen in liquid nitrogen and stored at80C until used for research in
this study, and the second partwas fixed in 10%buffered formalin for histologic
analysis. Of the proliferative phase tissue samples, a third part was kept apart
and directly used for endometrial explant cultures (see later). The endometrium
was dated according to clinical information with respect to the start of the last
menstrual period, which was reconfirmed by histologic examination of the
tissue (13).
Explant cultures Part of the proliferative phase endometrium tissue from
all 23 collected biopsy specimens was used for explant culture as describedTABLE 1
Primary antibodies and conditions used for immunohistochemica
Antibody Species Catalog no. IgG class Dilution
DNMT1 Goat sc-10222 IgG1 1:750 S
MBD2 Goat sc-9397 Not specified 1:500 S
5 MeCyt Mouse MCA2201 IgG1 1:100 A
Note: Tris-EDTA ¼ tris(hydroxymethyl)aminomethane–ethylenediaminetetraace
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(0.1% ethanol) or steroid hormones (E2, 1 nmol/L; P4, 1 nmol/L; E2 þ P4,
1 nmol/L each). At the end of the experiment, the explants were collected
in lysis buffer (SV Total RNA Isolation Kit; Promega, Madison, WI) and
stored at 80C until RNA isolation.
Tissues collected in the Leuven Fertility Clinic Patient material used
for the present investigation has been described before (15). In short, tissue
was obtained during the proliferative phase of the menstrual cycle from 34
women, including 20 women with laparoscopically confirmed absence of en-
dometriosis and 14 women with both laparoscopically and histologically
confirmed stage III to IVendometriosis (American Society for Reproductive
Medicine classification [16]). Both eutopic and ectopic tissue was harvested.
All patients had a regular menstrual cycle and were documented not to be
taking any steroid medication within 6 months before surgery.
Ribonucleic Acid Isolation and Complementary
Deoxyribonucleic Acid Synthesis
Total cellular RNA from the cultured explants and uncultured cyclic endome-
trium was extracted with use of the SV Total RNA Isolation Kit (Promega) ac-
cording to the manufacturer’s protocol. Ribonucleic acid from the tissue
samples collected in theLeuvenFertilityClinicwas isolatedwith use of theTRI-
zol reagent method (Invitrogen, Carlsbad, CA) according to the manufacturer’s
protocol.Ribonucleic acid quantityandqualitywereassessedwith a spectropho-
tometer at 260- and 280-nmwavelengths. For the production of complementary
DNA the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA) was used.
Real-time Polymerase Chain Reaction
TheTaqManGeneExpressionAssays forDNMT1 (Hs00154749_m1), DNMT2
(Hs00189402_m1), DNMT3B (Hs00171876_m1), MBD1 (Hs00242770_m1),
MBD2 (Hs00187506_m1), and MeCP2 (Hs00172845_m1), b-actin
(Hs99999903_m1), and cyclophilin A (Hs99999904_m1) were purchased
from Applied Biosystems (Foster City, CA). Human cyclophilin A was used
as housekeeping gene to normalize the differences in the amount of complemen-
tary DNA added to each PCR reaction. To check for the amount of endometrial
tissue present in eutopic and ectopic endometrial biopsies, the expression level of
17b-hydroxysteroid dehydrogenase 4 (17bHSD4), a gene previously shown to
be expressed at equal levels in eutopic endometrium and endometriotic tissue
(15), was measured.
Immunohistochemistry
A summary of the primary and secondary antibodies, antigen retrieval steps,
and incubation conditions used is given in Table 1. Antibody binding was
visualized with use of the Envision rabbit anti-mouse (for monoclonal anti-
bodies) or anti-goat (for goat polyclonal antibodies) ChemMate Detection
Kits (DAKO, Copenhagen, Denmark), followed by incubation with 3, 30-dia-
minobenzidine. Negative control slides for the monoclonal antibodies were
incubatedwithmouse IgGs of the same class and same dilution as the primary
antibodies. Negative control slides for the goat polyclonal antibodies were in-
cubated with goat IgG at the same dilution as the polyclonal antibodies.l analysis of eutopic endometrium and endometriosis lesions.
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Statistical Tests
Statistical tests were carried out with use of the Statistical Package for
the Social Sciences (version 16.0; SPSS Inc., Chicago, IL) statistical
analysis package. To evaluate whether expression levels varied signifi-
cantly throughout the menstrual cycle, the nonparametric unpairedFIGURE 1
Expression levels of DNMT1, DNMT2, DNMT3B, MBD1, MBD2, and MeC
and in eutopic endometrium of controls (normal), eutopic endometrium o
patients with endometriosis (ectopic) (B).
van Kaam. DNMTs and MBDs in endometriosis. Fertil Steril 2011.
Fertility and SterilityMann-Whitney U test was used to test for differences between these
expression levels versus the expression level in the M phase. The non-
parametric Wilcoxon signed-rank test was used to test for differences
between steroid-treated explants and controls at a confidence level of
95%.P2 in menstrual, proliferative and secretory phase endometrium (A)
f patients with endometriosis (eutopic), and ectopic endometrium of
1423
RESULTS
Deoxyribonucleic Acid Methyltransferases and Methyl-
CpG-binding Domain Protein Expression Throughout the
Menstrual Cycle
The relative expression level of DNMT1 was significantly higher in
secretory endometrium compared with proliferative (P¼.02) and
menstrual endometrium (P¼.009). Expression levels of DNMT2
and DNMT3B were not significantly different between the cycle
phases. Significantly higher expression levels of MBD2 were
observed in secretory endometrium compared with proliferative
(P¼.004) and menstrual (P¼.018) endometrium. There were noFIGURE 2
Representative photographs of DNMT1 (A), MBD2 (B) protein, and 5-m
menstrual cycle (proliferative phase and secretory phase) and in eutopi
van Kaam. DNMTs and MBDs in endometriosis. Fertil Steril 2011.
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throughout the menstrual cycle (Fig. 1A). Immunoreactivity for
DNMT1 (Fig. 2A), MBD2 (Fig. 2B), and 5-methylcytosine
(Fig. 2C) was observed in nuclei of epithelial and stromal cells of
both proliferative and secretory endometrium.
Expression levels of deoxyribonucleic acid methyltransferases and
methyl-CpG-binding domain proteins in explant cultures Because
transcript levels of DNMT1 and MBD2 were shown to be up-
regulated significantly in the secretory phase of the menstrual cycle,
hormonal regulation of these genes was hypothesized. Therefore,
the effect of cultivation with estrogen (E2) alone or estrogen inethylcytosine (C) expression in normal endometrium throughout the
c and ectopic endometrium of patients with endometriosis.
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FIGURE 2 Continued
van Kaam. DNMTs and MBDs in endometriosis. Fertil Steril 2011.combination with P (E2þ P) was assessed in explant cultures of pro-
liferative endometrium. Expression of DNMT1 was up-regulated
significantly by treatment with E2þ P (P¼.021) but not by treatment
with E2 alone (P¼.086). The same phenomenon was observed for
MBD2: expression levels were shown to be significantly higher
when endometrium was cultured with E2þ P (P¼.038) but not after
cultivation with E2 alone (Fig. 3).
Expression levels of deoxyribonucleic acid methyltransferases and
methyl-CpG-binding domain proteins in matched samples of
eutopic and ectopic endometrium Deoxyribonucleic acid methyl-
transferase 1 showed significantly lower expression levels in eutopic
(P¼.007) and ectopic (P¼.001) endometrium of patients with
endometriosis compared with eutopic endometrium of controls. Ex-FIGURE 3
Expression levels of DNMT1 and MBD2 in endometrial explant cultures
estrogen and P (E2þP). Data are presented as means  SEM. *P< .05 v
van Kaam. DNMTs and MBDs in endometriosis. Fertil Steril 2011.
Fertility and Sterilitypression levels of DNMT3B did not differ between eutopic endome-
trium of cases and controls but were significantly lower in ectopic
endometrium compared with eutopic endometrium of cases
(P¼.008) and controls (P¼.002). The expression of DNMT2 did
not vary between the groups. Expression levels of MeCP2 were
significantly higher in eutopic endometrium of controls compared
with eutopic endometrium of cases (P¼.02), butwhen theywere com-
pared with ectopic endometrium no statistically significant difference
could be observed. Expression levels of MBD1 on the other hand did
not vary between eutopic endometrium of controls and cases but were
significantly lower in ectopic endometrium compared with eutopic
endometrium of cases (P¼.017) and controls (P<.0001). Finally, sig-
nificantly lower expression levels of MBD2 were observed in eutopic
(P¼.001) and ectopic (P¼.0002) endometrium of cases comparedafter cultivation for 24 hours with estrogen (E2) or a combination of
ersus control (uncultured) endometrium.
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with eutopic endometrium of controls (Fig. 1B). Immunoreactivity for
DNMT1 (Fig. 2A), MBD2 (Fig. 2B), and 5-methylcytosine (Fig. 2C)
was observed in nuclei of epithelial and stromal cells of both eutopic
and ectopic endometrium of patients.DISCUSSION
In the present study, we observed cyclic variations in the expression
of DNMT1 andMBD2, with significantly higher expression levels of
both enzymes in secretory phase endometrium comparedwith prolif-
erative and menstrual phase endometrium. Furthermore, we showed
that the expression of these genes is regulated by steroid hormones.
Strikingly, our findings contradict the report of Yamagata et al. (11),
who found significantly reduced levels of DNMT1, DNMT3A, and
DNMT3B in the secretory phase of themenstrual cycle. In this study,
incubation of cultured proliferative phase endometrial stromal cells
with E2 and P resulted in significant down-regulation of DNMT3A
and DNMT3B. The expression of DNMT1 was not influenced under
these conditions (11). A possible explanation for this discrepancy
could be that the results of these authors were obtained in cultures
of isolated endometrial stromal cells, whereas in the present study
endometrial explant tissue cultures were used. It has been well
documented that stromal-epithelial interactions are indispensable
for the hormonal responses of the endometrium (17).
DNMT1 is considered the maintenance DNMT, because its pri-
mary function is to copy an already established DNA methylation
pattern after replication.On the basis of this functional characteristic,
it would be expected that DNMT1 expression levels are highest in the
proliferative phase of the menstrual cycle. However, in the present
study expression levels ofDNMT1 in the secretory phasewere shown
to exceed those in the proliferative phase. Interestingly, it has been
shown that DNMT1-depleted isolated embryonic stem cells remain
viable and proliferative but die on induction of differentiation
(18–20). Also, targeted deletion of DNMT1 in mouse embryos
proved to be lethal, with embryonic death occurring during or after
gastrulation when the pluripotent embryonic stem cells begin to
differentiate. These findings indicate a role for DNMT1 not only in
proliferating cells but also in the subsequent differentiation of cells.
The second protein that was shown to be up-regulated signifi-
cantly in the secretory phase is MBD2. There is no evidence for
an essential embryonic function for any mammalian MBD (21),
illustrated by the fact that MBD2- and MeCP2-null mice are viable
and fertile and display no overt phenotype (22, 23). However, there
is evidence for overlapping functions in differentiation and
specification of neural stem cells in culture and in postnatal
animals (21). Furthermore, it was shown that MeCP2 and MBD2
expression increases during (terminal) differentiation (24), which1426 van Kaam et al. DNMTs and MBDs in endometriosisis in line with our finding of elevated expression levels of MBD2
in secretory phase endometrium.
In the present study we also show that expression levels of
DNMT1 and MBD2 are significantly lower in eutopic and ectopic
endometrium of patients with endometriosis compared with eutopic
endometrium of controls, whereas MeCP2 expression is lower in eu-
topic than in ectopic endometrium of patients with endometriosis.
Finally, expression levels of DNMT3B and MBD1 are lower in
ectopic endometrium compared with eutopic endometrium of both
patients with endometriosis and controls.
Our findings do not confirm the observations of Wu et al. (12),
who found increased expression levels of DNMT1, DNMT3A, and
DNMT3B in ectopic endometrium as compared with disease-free
control subjects and eutopic endometrium of women with endome-
triosis. Possible explanations for this discrepancy may be related
to the heterogeneous patient population used by Wu et al. (12)
(menstrual, proliferative, and secretory phase endometrium vs.
only proliferative phase endometrium in the present study) and the
use of isolated endometrial epithelial cells rather than tissue cultures.
As stated earlier, DNMT1, MBD2, and MeCP2 appear to be indis-
pensable for tissue-specific gene expression and differentiation. The
findings obtained in the present study may signify that both eutopic
and ectopic endometrium of patientswith endometriosis has a reduced
capacity for differentiation and, hence, decidualization and implanta-
tion. Circumstantial evidence in support of this notion has been pro-
vided by numerous studies: aberrant expression of progesterone
receptor in endometriotic tissue (25–27), the absence of 17bHSD2
in eutopic and ectopic endometrium of patients with endometriosis
in the secretory phase (28), and altered expression of HOXA10 in eu-
topic and ectopic endometriumofpatientswithendometriosis (29, 30).
Furthermore, levels of the decidualization markers prolactin and
insulin-like growth factor binding protein-1 are reduced in superna-
tants from endometrial stromal cells derived from ectopic lesions
and from eutopic endometrium of women with endometriosis (31).
In conclusion, we have shown that expression levels of DNMT1
and MBD2 vary throughout the menstrual cycle. Their anticipated
dependence on steroid hormones was confirmed in explant cultures
prepared from proliferative phase endometrium tissue. The signifi-
cant reduction in the expression of various DNMTs andMBDs in ec-
topic endometrium of patients with endometriosis may explain why
altered gene promoter methylation has been observed in endometri-
otic lesions. That these changes in methylation status are also asso-
ciated with changes in phenotype, that is, gene expression, supports
the notion that endometriosis may be an epigenetic disease.Acknowledgment: The steroid hormones were a gift from Organon N.V., Oss,
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